Prostaglandin Mediators

Handbook of Cell Signaling, Second Edition

Volumn 2, Issue , 2009, Pages 1219-1228

  Smyth, Emer M ^a   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950208033     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374145-5.00150-9     Document Type: Chapter

References (149)

1. CC Leslie (1997) Properties and regulation of cytosolic phospholipase A2. J Biol Chem 272 16,709-16,712.
2. C Patrono and GA FitzGerald (1997) Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17 2309-2315.
3. HR Herschman (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299 125-140.
4. RM Garavito, D Picot and PJ Loll (1995) The 3.1A X-ray crystal structure of the integral membrane enzyme prostaglandin H2 synthase-1. Adv Prostaglandin Thromboxane Leukot Res 23 99-103.
5. SM Wijeyaratne, CR Abbott, S Homer-Vanniasinkam, AI Mavor and MJ Gough (2001) Differences in the detection of cyclo-oxygenase 1 and 2 proteins in symptomatic and asymptomatic carotid plaques. Br J Surg 88 951-957.
6. MA Iniguez, JL Pablos, PE Carreira, F Cabre and JJ Gomez-Reino (1998) Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. Br J Rheumatol 37 773-778.
7. M Wada, CJ DeLong, YH Hong, CJ Rieke, I Song, RS Sidhu, C Yuan, M Warnock, AH Schmaier, C Yokoyama, EM Smyth, SJ Wilson, GA FitzGerald, RM Garavito, X Sui de, JW Regan and WL Smith (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282 22,254-22,266.
8. WL Smith, RM Garavito and DL DeWitt (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271 33,157-33,160.
9. GA FitzGerald and P Loll (2001) COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 107 1335-1337.
10. AG Spencer, JW Woods, T Arakawa, I Singer and WL Smith (1998) Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 273 9886-9893.
11. N Ueno, M Murakami, T Tanioka, K Fujimori, T Tanabe, Y Urade and I Kudo (2001) Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem 276 34,918-34,927.
12. T Tanioka, Y Nakatani, N Semmyo, M Murakami and I Kudo (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275 32,775-32,782.
13. M Murakami, H Naraba, T Tanioka, N Semmyo, Y Nakatani, F Kojima, T Ikeda, M Fueki, A Ueno, S Oh and I Kudo (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275 32,783-32,792.
14. A Nagata, Y Suzuki, M Igarashi, N Eguchi, H Toh, Y Urade and O Hayaishi (1991) Human brain prostaglandin D synthase has been evolutionarily differentiated from lipophilic-ligand carrier proteins. Proc Natl Acad Sci USA 88 4020-4024.
15. Y Kanaoka, H Ago, E Inagaki, T Nanayama, M Miyano, R Kikuno, Y Fujii, N Eguchi, H Toh, Y Urade and O Hayaishi (1997) Cloning and crystal structure of hematopoietic prostaglandin D synthase. Cell 90 1085-1095.
16. K Watanabe, Y Fujii, K Nakayama, H Ohkubo, S Kuramitsu, H Kagamiyama, S Nakanishi and O Hayaishi (1988) Structural similarity of bovine lung prostaglandin F synthase to lens epsilon-crystallin of the European common frog. Proc Natl Acad Sci USA 85 11-15.
17. T Suzuki, Y Fujii, M Miyano, LY Chen, T Takahashi and K Watanabe (1999) cDNA cloning, expression, and mutagenesis study of liver-type prostaglandin F synthase. J Biol Chem 274 241-248.
18. H Lim, BC Paria, SK Das, JE Dinchuk, R Langenbach, JM Trzaskos and SK Dey (1997) Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91 197-208.
19. R Langenbach, SG Morham, HF Tiano, CD Loftin, BI Ghanayem, PC Chulada, JF Mahler, CA Lee, EH Goulding, KD Kluckman, et al. (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83 483-492.
20. GA Gross, T Imamura, C Luedke, SK Vogt, LM Olson, DM Nelson, Y Sadovsky and LJ Muglia (1998) Opposing actions of prostaglandins and oxytocin determine the onset of murine labor. Proc Natl Acad Sci USA 95 11,875-11,879.
21. CD Loftin, DB Trivedi, HF Tiano, JA Clark, CA Lee, JA Epstein, SG Morham, MD Breyer, M Nguyen, BM Hawkins, JL Goulet, O Smithies, BH Koller and R Langenbach (2001) Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA 98 1059-1064.
22. KG Coggins, A Latour, MS Nguyen, L Audoly, TM Coffman and BH Koller (2002) Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med 8 91-92.
23. YI Cha and RN DuBois (2007) NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58 239-252.
24. T Grosser, S Yusuff, E Cheskis, MA Pack and GA FitzGerald (2002) Developmental Expression of Functional Cyclooxygenases in Zebrafish. Proc Natl Acad Sci USA 14 14.
25. B Rocca, LM Spain, E Pure, R Langenbach, C Patrono and GA FitzGerald (1999) Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 103 1469-1477.
26. S Narumiya, Y Sugimoto and F Ushikubi (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79 1193-1226.
27. K Nagata, H Hirai, K Tanaka, K Ogawa, T Aso, K Sugamura, M Nakamura and S Takano (1999) CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Letts 459 195-199.
28. H Hirai, K Tanaka, O Yoshie, K Ogawa, K Kenmotsu, Y Takamori, M Ichimasa, K Sugamura, M Nakamura, S Takano and K Nagata (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193 255-261.
29. MK Raychowdhury, M Yukawa, LJ Collins, SH McGrail, KC Kent and JA Ware (1994) Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 269 19,256-19,261.
30. KL Pierce, TJ Bailey, PB Hoyer, DW Gil, DF Woodward and JW Regan (1997) Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J Biol Chem 272 883-887.
31. A Schmid, KH Thierauch, WD Schleuning and H Dinter (1995) Splice variants of the human EP3 receptor for prostaglandin E2. Eur J Biochem 228 23-30.
32. RM Breyer, CK Bagdassarian, SA Myers and MD Breyer (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41 661-690.
33. GW Dorn II, D Sens, A Chaikhouni, D Mais and PV Halushka (1987) Cultured human vascular smooth muscle cells with functional thromboxane A2 receptors: measurement of U46619-induced 45calcium efflux. Circ Res 60 952-956.
34. R Pakala, JT Willerson and CR Benedict (1997) Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96 2280-2286.
35. GA FitzGerald (1991) Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 68 11B-15B.
36. C Patrono (1994) Aspirin as an antiplatelet drug. N Engl J Med 330 1287-1294.
37. AJ Cayatte, Y Du, J Oliver-Krasinski, G Lavielle, TJ Verbeuren and RA Cohen (2000) The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20 1724-1728.
38. S Ali II, MG Davis, MW Becker and GW Dorn (1993) Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 268 17,397-17,403.
39. P Pradono, R Tazawa, M Maemondo, M Tanaka, K Usui, Y Saijo, K Hagiwara and T Nukiwa (2002) Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62 63-66.
40. GW Dorn II and A DeJesus (1991) Human platelet aggregation and shape change are coupled to separate thromboxane A2-prostaglandin H2 receptors. Am J Physiol 260 H327-H334.
41. A Habib, GA FitzGerald and J Maclouf (1999) Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 274 2645-2651.
42. T Hirata, A Kakizuka, F Ushikubi, I Fuse, M Okuma and S Narumiya (1994) Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 94 1662-1667.
43. R Vezza, A Habib and GA FitzGerald (1999) Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. J Biol Chem 274 12,774-12,779.
44. T Hirata, F Ushikubi, A Kakizuka, M Okuma and S Narumiya (1996) Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 97 949-956.
45. M Yukawa, R Yokota, RT Eberhardt, L von Andrian and JA Ware (1997) Differential desensitization of thromboxane A2 receptor subtypes. Circ Res 80 551-556.
46. JL Parent, P Labrecque, MJ Orsini and JL Benovic (1999) Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 274 8941-8948.
47. J Takasaki, M Kamohara, T Saito, M Matsumoto, S Matsumoto, T Ohishi, T Soga, H Matsushime and K Furuichi (2001) Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol 60 432-439.
48. LP Audoly, B Rocca, JE Fabre, BH Koller, D Thomas, AL Loeb, TM Coffman and GA FitzGerald (2000) Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 101 2833-2840.
49. SJ Wilson, K McGinley, AJ Huang and EM Smyth (2007) Heterodimerization of the alpha and beta isoforms of the human thromboxane receptor enhances isoprostane signaling. Biochem Biophys Res Commun 352 397-403.
50. LA Devi (2001) Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 22 532-537.
51. SJ Wilson, AM Roche, E Kostetskaia and EM Smyth (2004) Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem 279 53,036-53,047.
52. SM Miggin and BT Kinsella (1998) Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1425 543-559.
53. TF Leung, NL Tang, CW Lam, AM Li, IH Chan and G Ha (2002) Thromboxane A2 receptor gene polymorphism is associated with the serum concentration of cat-specific immunoglobulin E as well as the development and severity of asthma in Chinese children. Pediatr Allergy Immunol 13 10-17.
54. DW Thomas, RB Mannon, PJ Mannon, A Latour, JA Oliver, M Hoffman, O Smithies, BH Koller and TM Coffman (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 102 1994-2001.
55. T Kobayashi, Y Tahara, M Matsumoto, M Iguchi, H Sano, T Murayama, H Arai, H Oida, T Yurugi-Kobayashi, JK Yamashita, H Katagiri, M Majima, M Yokode, T Kita and S Narumiya (2004) Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114 784-794.
56. Y Cheng, SC Austin, B Rocca, BH Koller, TM Coffman, T Grosser, JA Lawson and GA FitzGerald (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296 539-541.
57. B Rocca III, AL Loeb, JF Strauss, R Vezza, A Habib, H Li and GA FitzGerald (2000) Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med 6 219-221.
58. F Catella-Lawson, B McAdam, BW Morrison, S Kapoor, D Kujubu, L Antes, KC Lasseter, H Quan, BJ Gertz and GA FitzGerald (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289 735-741.
59. S Moncada and JR Vane (1981) Prostacyclin: homeostatic regulator or biological curiosity? Clin Sci (Colch) 61 369-372.
60. TP Zucker, D Bonisch, A Hasse, T Grosser, AA Weber and K Schror (1998) Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. Eur J Pharmacol 345 213-220.
61. DJ Fitzgerald, L Roy, F Catella and GA FitzGerald (1986) Platelet activation in unstable coronary disease. N Engl J Med 315 983-989.
62. DJ Fitzgerald, J Doran, E Jackson and GA FitzGerald (1986) Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. J Clin Invest 77 496-502.
63. VV McLaughlin, DE Genthner, MM Panella and S Rich (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 273-277.
64. Y Numaguchi, K Naruse, M Harada, H Osanai, S Mokuno, K Murase, H Matsui, Y Toki, T Ito, K Okumura and T Hayakawa (1999) Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 19 727-733.
65. T Nakayama, M Soma, D Rahmutula, H Tobe, M Sato, J Uwabo, N Aoi, K Kosuge, M Kunimoto, K Kanmatsuse and S Kokubun (2002) Association study between a novel single nucleotide polymorphism of the promoter region of the prostacyclin synthase gene and essential hypertension. Hypertens Res 25 65-68.
66. T Nakayama, M Soma, D Rehemudula, Y Takahashi, H Tobe, M Satoh, J Uwabo, M Kunimoto and K Kanmatsuse (2000) Association of 5′ upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. Am J Hypertens 13 1263-1267.
67. Z Qi, H Chuan-Ming, RI Langenbach, RM Breyer, R Redha, JD Morrow and MD Breyer (2002) Opposite effects of cyclooxygenases 1 and 2 activity on the pressor response to angiotensin II. J Clin Invest. 110 61-69.
68. JK Hennan, J Huang, TD Barrett, EM Driscoll, DE Willens, AM Park, LJ Crofford and BR Lucchesi (2001) Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104 820-825.
69. SR Adderley and DJ Fitzgerald (1999) Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274 5038-5046.
70. T Namba, H Oida, Y Sugimoto, A Kakizuka, M Negishi, A Ichikawa and S Narumiya (1994) cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 269 9986-9992.
71. RL Hebert, L Regnier and LN Peterson (1995) Rabbit cortical collecting ducts express a novel prostacyclin receptor. Am J Physiol 268 F145-F154.
72. H Takechi, K Matsumura, Y Watanabe, K Kato, R Noyori and M Suzuki (1996) A novel subtype of the prostacyclin receptor expressed in the central nervous system. J Biol Chem 271 5901-5906.
73. BM Forman, J Chen and RM Evans (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94 4312-4317.
74. JM Peters, SS Lee, W Li, JM Ward, O Gavrilova, C Everett, ML Reitman, LD Hudson and FJ Gonzalez (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 20 5119-5128.
75. E Arehart, J Stitham, FW Asselbergs, K Douville, T MacKenzie, KM Fetalvero, S Gleim, Z Kasza, Y Rao, L Martel, S Segel, J Robb, A Kaplan, M Simons, RJ Powell, JH Moore, EB Rimm, KA Martin and J Hwa (2008) Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 102 986-993.
76. T Murata, F Ushikubi, T Matsuoka, M Hirata, A Yamasaki, Y Sugimoto, A Ichikawa, Y Aze, T Tanaka, N Yoshida, A Ueno, S Oh-ishi and S Narumiya (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 678-682.
77. Y Cheng, M Wang, Y Yu, J Lawson, CD Funk and GA Fitzgerald (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116 1391-1399.
78. Y Hoshikawa, NF Voelkel, TL Gesell, MD Moore, KG Morris, LA Alger, S Narumiya and MW Geraci (2001) Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 164 314-318.
79. H Francois, K Athirakul, D Howell, R Dash, L Mao, HS Kim, HA Rockman, GA Fitzgerald, BH Koller and TM Coffman (2005) Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2 201-207.
80. AK Lovgren, LA Jania, JM Hartney, KK Parsons, LP Audoly, GA Fitzgerald, SL Tilley and BH Koller (2006) COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 291 L144-L156.
81. W Zhou, K Hashimoto, K Goleniewska, JF O’Neal, S Ji, TS Blackwell, GA Fitzgerald, KM Egan, MW Geraci and RS Peebles Jr (2007) Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 178 702-710.
82. K Egan, S Austin, EM Smyth and GA FitzGerald (2000) Accelerated atherogenesis in protacyclin receptor deficient mice. Circulation 102 234.
83. H Seeger, AO Mueck and TH Lippert (1999) Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sci 65 L167-L170.
84. C Yokoyama, T Yabuki, M Shimonishi, M Wada, T Hatae, S Ohkawara, J Takeda, T Kinoshita, M Okabe and T Tanabe (2002) Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106 2397-2403.
85. K Sladek II, JR Sheller, GA FitzGerald, JD Morrow and LJ Roberts (1991) Formation of PGD2 after allergen inhalation in atopic asthmatics. Adv Prostaglandin Thromboxane Leukot Res 433-436.
86. LJ Roberts II, BJ Sweetman, RA Lewis, KF Austen and JA Oates (1980) Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 303 1400-1404.
87. WL Song, M Wang, E Ricciotti, S Fries, Y Yu, T Grosser, M Reilly, JA Lawson and GA FitzGerald (2008) Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem 283 1179-1188.
88. DJ Heavey, P Lumley, SE Barrow, MB Murphy, PP Humphrey and CT Dollery (1984) Effects of intravenous infusions of prostaglandin D2 in man. Prostaglandins 28 755-767.
89. Y Fujitani, Y Kanaoka, K Aritake, N Uodome, K Okazaki-Hatake and Y Urade (2002) Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 168 443-449.
90. T Inoue, K Takayanagi, S Morooka, Y Uehara, H Oda, K Seiki, H Nakajima and Y Urade (2001) Serum prostaglandin D synthase level after coronary angioplasty may predict occurrence of restenosis. Thromb Haemost 85 165-170.
91. E Noguchi, M Shibasaki, M Kamioka, Y Yokouchi, K Yamakawa-Kobayashi, H Hamaguchi, A Matsui and T Arinami (2002) New polymorphisms of haematopoietic prostaglandin D synthase and human prostanoid DP receptor genes. Clin Exp Allergy 32 93-96.
92. O Hayaishi (2000) Molecular mechanisms of sleep–wake regulation: a role of prostaglandin D2. Philos Trans R Soc Lond B Biol Sci 355 275-280.
93. N Eguchi, T Minami, N Shirafuji, Y Kanaoka, T Tanaka, A Nagata, N Yoshida, Y Urade, S Ito and O Hayaishi (1999) Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA 96 726-730.
94. G Monneret, S Gravel, M Diamond, J Rokach and WS Powell (2001) Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98 1942-1948.
95. R Pettipher, TT Hansel and R Armer (2007) Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 6 313-325.
96. T Michimata, H Tsuda, M Sakai, M Fujimura, K Nagata, M Nakamura and S Saito (2002) Accumulation of CRTH2-positive T-helper 2 and T-cytotoxic 2 cells at implantation sites of human decidua in a prostaglandin D(2)-mediated manner. Mol Hum Reprod 8 181-187.
97. G Monneret, H Li, J Vasilescu, J Rokach and WS Powell (2002) 15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J Immunol 168 3563-3569.
98. SG Harris, J Padilla, L Koumas, D Ray and RP Phipps (2002) Prostaglandins as modulators of immunity. Trends Immunol 23 144-150.
99. BM Forman, P Tontonoz, J Chen, RP Brun, BM Spiegelman and RM Evans (1995) 15–Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 803-812.
100. T Matsuoka, M Hirata, H Tanaka, Y Takahashi, T Murata, K Kabashima, Y Sugimoto, T Kobayashi, F Ushikubi, Y Aze, N Eguchi, Y Urade, N Yoshida, K Kimura, A Mizoguchi, Y Honda, H Nagai and S Narumiya (2000) Prostaglandin D2 as a mediator of allergic asthma. Science 287 2013-2017.
101. A Mizoguchi, N Eguchi, K Kimura, Y Kiyohara, WM Qu, ZL Huang, T Mochizuki, M Lazarus, T Kobayashi, T Kaneko, S Narumiya, Y Urade and O Hayaishi (2001) Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proc Natl Acad Sci USA 98 11,674-11,679.
102. T Satoh, R Moroi, K Aritake, Y Urade, Y Kanai, K Sumi, H Yokozeki, H Hirai, K Nagata, T Hara, M Utsuyama, K Hirokawa, K Sugamura, K Nishioka and M Nakamura (2006) Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 177 2621-2629.
103. E Chevalier, J Stock, T Fisher, M Dupont, M Fric, H Fargeau, M Leport, S Soler, S Fabien, MP Pruniaux, M Fink, CP Bertrand, J McNeish and B Li (2005) Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol 175 2056-2060.
104. K Cheng, TJ Wu, KK Wu, C Sturino, K Metters, K Gottesdiener, SD Wright, Z Wang, G O’Neill, E Lai and MG Waters (2006) Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 103 6682-6687.
105. RN Dubois, SB Abramson, L Crofford, RA Gupta, LS Simon, LB Van De Putte and PE Lipsky (1998) Cyclooxygenase in biology and disease. Faseb J 12 1063-1073.
106. SJ Lydford, KC McKechnie and IG Dougall (1996) Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br J Pharmacol 117 13-20.
107. RA Coleman, I Kennedy, PPA Humphrey, K Bunce and P Lumley (1990) Prostanoids and their receptors. C Hansch (Ed.) Comprehensive medicinal chemistry Oxford: Pergamon Press 643-714.
108. B Samuelsson, R Morgenstern and PJ Jakobsson (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59 207-224.
109. CE Trebino, JL Stock, CP Gibbons, BM Naiman, TS Wachtmann, JP Umland, K Pandher, JM Lapointe, S Saha, ML Roach, D Carter, NA Thomas, BA Durtschi, JD McNeish, JE Hambor, PJ Jakobsson, TJ Carty, JR Perez and LP Audoly (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 100 9044-9049.
110. M Wang, AM Zukas, Y Hui, E Ricciotti, E Pure and GA FitzGerald (2006) Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 103 14,507-14,512.
111. Wang M, Lee E, Song W, Ricciotti E, Rader DJ, Lawson JA, Pure E, Fitzgerald GA. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 2008. in press.
112. T Yang, I Singh, H Pham, D Sun, A Smart, JB Schnermann and JP Briggs (1998) Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 274 F481-F489.
113. MD Breyer and RM Breyer (2000) Prostaglandin E receptors and the kidney. Am J Physiol Renal Physiol 279 F12-F23.
114. Z Jia, A Zhang, H Zhang, Z Dong and T Yang (2006) Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 99 1243-1251.
115. Y Sugimoto and S Narumiya (2007) Prostaglandin E receptors. J Biol Chem 282 11,613-11,617.
116. JE Fabre, M Nguyen, K Athirakul, K Coggins, JD McNeish, S Austin, LK Parise, GA FitzGerald, TM Coffman and BH Koller (2001) Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 107 603-610.
117. CR Kennedy, Y Zhang, S Brandon, Y Guan, K Coffee, CD Funk, MA Magnuson, JA Oates, MD Breyer and RM Breyer (1999) Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 5 217-220.
118. BL Jensen, C Schmid and A Kurtz (1996) Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol 271 F659-F669.
119. EW Inscho, PK Carmines and LG Navar (1990) Prostaglandin influences on afferent arteriolar responses to vasoconstrictor agonists. Am J Physiol 259 F157-F163.
120. H Araki, H Ukawa, Y Sugawa, K Yagi, K Suzuki and K Takeuchi (2000) The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach. Aliment Pharmacol Ther 14(Suppl. 1), 116-124.
121. T Kunikata, A Tanaka, T Miyazawa, S Kato and K Takeuchi (2002) 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 47 894-904.
122. G Asboth, S Phaneuf, GN Europe-Finner, M Toth and AL Bernal (1996) Prostaglandin E2 activates phospholipase C and elevates intracellular calcium in cultured myometrial cells: involvement of EP1 and EP3 receptor subtypes. Endocrinology 137 2572-2579.
123. K Tani, A Naganawa, A Ishida, H Egashira, K Sagawa, H Harada, M Ogawa, T Maruyama, S Ohuchida, H Nakai, K Kondo and M Toda (2001) Design and synthesis of a highly selective EP2-receptor agonist. Bioorg Med Chem Letts 11 2025-2028.
124. M Sonoshita, K Takaku, N Sasaki, Y Sugimoto, F Ushikubi, S Narumiya, M Oshima and MM Taketo (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7 1048-1051.
125. R Pai, B Soreghan, IL Szabo, M Pavelka, D Baatar and AS Tarnawski (2002) Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 289-293.
126. C Nataraj, DW Thomas, SL Tilley, MT Nguyen, R Mannon, BH Koller and TM Coffman (2001) Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest 108 1229-1235.
127. M Ek, D Engblom, S Saha, A Blomqvist, PJ Jakobsson and A Ericsson-Dahlstrand (2001) Inflammatory response: pathway across the blood-brain barrier. Nature 410 430-431.
128. Y Yoshida, H Matsumura, T Nakajima, M Mandai, T Urakami, K Kuroda and H Yoneda (2000) Prostaglandin E (EP) receptor subtypes and sleep: promotion by EP4 and inhibition by EP1/EP2. Neuroreport 11 2127-2131.
129. F Ushikubi, E Segi, Y Sugimoto, T Murata, T Matsuoka, T Kobayashi, H Hizaki, K Tuboi, M Katsuyama, A Ichikawa, T Tanaka, N Yoshida and S Narumiya (1998) Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395 281-284.
130. JL Stock, K Shinjo, J Burkhardt, M Roach, K Taniguchi, T Ishikawa, HS Kim, PJ Flannery, TM Coffman, JD McNeish and LP Audoly (2001) The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 107 325-331.
131. EF Fleming, K Athirakul, MI Oliverio, M Key, J Goulet, BH Koller and TM Coffman (1998) Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2. Am J Physiol 275 F955-F961.
132. M Nguyen, T Camenisch, JN Snouwaert, E Hicks, TM Coffman, PA Anderson, NN Malouf and BH Koller (1997) The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature 390 78-81.
133. AM Fulton, X Ma and N Kundu (2006) Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 66 9794-9797.
134. EW Horton and NL Poyser (1976) Uterine luteolytic hormone: a physiological role for prostaglandin F2alpha. Physiol Rev 56 595-651.
135. YJ Dong, RL Jones and NH Wilson (1986) Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br J Pharmacol 87 97-107.
136. JW Barnard, RA Ward and AE Taylor (1992) Evaluation of prostaglandin F2 alpha and prostacyclin interactions in the isolated perfused rat lung. J Appl Physiol 72 2469-2474.
137. T Suzuki-Yamamoto, M Nishizawa, M Fukui, E Okuda-Ashitaka, T Nakajima, S Ito and K Watanabe (1999) cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Letts 462 335-340.
138. K Endo, M Fukui, M Mishima and K Watanabe (2001) Metabolism of vitamin A affected by prostaglandin F synthase in contractile interstitial cells of bovine lung. Biochem Biophys Res Commun 287 956-961.
139. H Vanegas and HG Schaible (2001) Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog Neurobiol 64 327-363.
140. JW Adams, DS Migita, MK Yu, R Young, MS Hellickson, FE Castro-Vargas, JD Domingo, PH Lee, JS Bui and SA Henderson (1996) Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 271 1179-1186.
141. KL Pierce, H Fujino, D Srinivasan and JW Regan (1999) Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J Biol Chem 274 35,944-35,949.
142. H Fujino, D Srinivasan, KL Pierce and JW Regan (2000) Differential regulation of prostaglandin F(2alpha) receptor isoforms by protein kinase C. Mol Pharmacol 57 353-358.
143. H Fujino and JW Regan (2001) FP prostanoid receptor activation of a T-cell factor/beta -catenin signaling pathway. J Biol Chem 276 12,489-12,492.
144. P Kunapuli, JA Lawson, J Rokach and GA FitzGerald (1997) Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor. Activation by the isoprostane, 12-iso-PGF2alpha. J Biol Chem 272 27,147-27,154.
145. TR Hesketh, JP Moore, JD Morris, MV Taylor, J Rogers, GA Smith and JC Metcalfe (1985) A common sequence of calcium and pH signals in the mitogenic stimulation of eukaryotic cells. Nature 313 481-484.
146. P Kunapuli, JA Lawson, JA Rokach, JL Meinkoth and GA FitzGerald (1998) Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem 273 22,442-22,452.
147. DA Casimir, CW Miller and JM Ntambi (1996) Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells. Differentiation 60 203-210.
148. Y Sugimoto, A Yamasaki, E Segi, K Tsuboi, Y Aze, T Nishimura, H Oida, N Yoshida, T Tanaka, M Katsuyama, K Hasumoto, T Murata, M Hirata, F Ushikubi, M Negishi, A Ichikawa and S Narumiya (1997) Failure of parturition in mice lacking the prostaglandin F receptor. Science 277 681-683.
149. K Tsuboi, Y Sugimoto, A Iwane, K Yamamoto, S Yamamoto and A Ichikawa (2000) Uterine expression of prostaglandin H2 synthase in late pregnancy and during parturition in prostaglandin F receptor-deficient mice. Endocrinology 141 315-324.